Please login to the form below
Abivax
This page shows the latest Abivax news and features for those working in and with pharma, biotech and healthcare.
Abivax enrols first patient in global phase 3 programme with obefazimod in ulcerative colitis
Abivax has enrolled the first patients in its global phase 3 clinical programme, ABTECT, with obefazimod for the treatment of moderate to severe ulcerative colitis (UC), the company announced. ... reported. Abivax outlined that 1, 200 UC patients will
Latest news
-
Abivax’s COVID-19 study declared Research National Priority by French government
Abivax is devoting significant efforts to this major international clinical trial and simultaneously accelerating ABX464 manufacturing scale-up for potential 2021 commercialisation,” he added. ... In July, Abivax treated the first patient in the phase
-
AbbVie, Amgen and Takeda team up for joint COVID-19 trial
French biotech company Abivax is also currently investigating its experimental ulcerative colitis drug ABX464 as an early treatment for elderly or high-risk patients with COVID-19.
-
Roche’s Actemra fails in late-stage severe COVID-19 study
Another anti-inflammatory drug, ABX464, is currently being studied by Abivax as an early treatment for elderly or high-risk patients with confirmed COVID-19.
-
Mesoblast expands compassionate use COVID-19 programme
A host of candidates are being investigated to regulate the overactive inflammatory side effects associated with some cases of COVID-19, including Abivax’s experimental anti-inflammatory med ABX464. ... Last week, Abivax initiated a phase 2b/3 study
-
Abivax doses first patient in phase 2b/3 COVID-19 clinical trial
Study will evaluate experimental anti-inflammatory drug. French biotech company Abivax has treated the first patient in a phase 2b/3 study of its experimental anti-inflammatory drug ABX464 in ... Currently, Abivax has received approval for studies in
More from news
Approximately 4 fully matching, plus 4 partially matching documents found.
Latest Intelligence
-
The race for a HIV ‘cure’
Another company working on a similar candidate is French biotech Abivax.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- Home Based Account Manager, Medical Communications, UK, Pharma/M...
- Highly competitive salary
- Account Manager, 6 month contract, Healthcare Brand communicatio...
- Highly competitive salary
- Senior Medical Copywriter - Highly Awarded Advertising Agency
- £50,000 - £60,000 yearly
- Market Access Director, six figure base salary and £5K joining b...
- Highly competitive salary
- Account Manager, Healthcare Marketing Creative Agency, Fixed ter...
- Highly competitive salary
- Account Director, Healthcare Marketing Creative Agency, Fixed te...
- Highly competitive salary
- AbbVie’s Rinvoq receives FDA approval for Crohn’s disease
- AstraZeneca announces positive phase 3 results for Tagrisso combination in lung cancer
- Bayer’s Nubeqa combination recommended by NICE to treat metastatic prostate cancer
- Bristol Myers Squibb presents positive results for idiopathic pulmonary fibrosis drug
- Novo Nordisk announces positive phase 3 results for oral weight-loss drug
- Sanofi reports positive new data for multiple sclerosis treatment tolebrutinib
- Medscape Medical Affairs Selected as Finalist for 2023 Communiqué Awards
- COVID-19: Pfizer’s Paxlovid approved by FDA and Gilead’s Veklury recommended by CHMP
- BMS and Janssen’s antithrombotic granted FDA fast track designation
- Gene therapy, gene editing and perspectives on future use in Parkinson’s disease
- Patient Clinical Trial & Communications Plan Review: A Customer Story
- Shining a Spotlight on Women’s Health Education Outcomes at ACOG 2023
PMHub
Oxford University Press
Oxford University Press publishes over 100 prestigious, highly cited, and authoritative medical journals, many in collaboration with some of the...
Latest intelligence
- Patient Clinical Trial & Communications Plan Review: A Customer Story
- ...
- Working together to achieve better patient pathways
- Digital tools can supercharge patient treatment and outcomes but the importance of the patient voice cannot be underestimated...
- Design-thinking. Iterating for continuous improvement.
- How design can lead improvement within Pharma...
